



Short profile Newsight Imaging

CHARITÉ/BIH-PARTNER WANTED!
More information [here](#)

Medical field	Oncology, Telemedicine
Product	SpectraLIT™, Medical Device/Diagnostics/AI
Growth stage	R&D, positioning for scale
Founders	Eli Assoolin (Co-founder, CEO), Eyal Yatskan (Co-founder, CTO)

Description of product:

The technology is based on Newsight Imaging's revolutionary sensor, the NSP2020, that serves as a spectrometer on chip. The small-sized spectral chip detects light intensity in wavelengths that range between 400nm and 700nm and provides 1024 digital values with up-to 12bit. Each value represents the intensity at each wavelength, which allows the creation of high-resolution spectral profiles of any tested substance. SpectraLIT™ allows professionals to evaluate and diagnose patients at a distance, while getting immediate results. The device is portable, low cost and cloud connected, powered by AI and machine learning. Using a special developed algorithm, SpectraLIT™ can compare the tested substances' spectral signature to signatures located on a local or remote database, allowing detection and identification of the sample to matching substances previously analyzed by SpectraLIT™.

Project goal:

Newsight Imaging is hoping to achieve a clinical breakthrough with its partner, that will lead to a shared designing of a spectral device that will address telemedicine difficulties.

Project type:

Newsight is looking for leading worldwide hospitals with proven track record, that can bring the technology to the next level and guide the company through breakthrough discoveries. Newsight's engagement model is very flexible and we are open to establish joint ventures. The co-development will result in accurate point of care testing and in finding new and exciting cases together. Estimated Time for Validation: 6 months. Estimated Project Duration: One Year.



Eligible by the IIA



mor.lerner@nstimg.com



Mor Lerner: 972525584048



www.nstimg.com

